Agios Pharmaceuticals Inc (STU:8AP)
€ 42 2.6 (6.6%) Market Cap: 2.40 Bil Enterprise Value: 1.91 Bil PE Ratio: 0 PB Ratio: 3.45 GF Score: 41/100

Agios Pharmaceuticals Inc to Present Mitapivat Clinical Data at EHA Virtual Congress Transcript

Jun 11, 2021 / 11:30AM GMT
Release Date Price: €48.88 (-0.59%)
Steve Klass

Good morning, everyone, and thank you for joining the Agios EHA Investor Event. (Operator Instructions)

Also, I want to note that a copy of the slide deck is available on the Agios Investor Relations section of the Agios website.

I will now turn the call over to Jackie.

Jacqualyn A. Fouse
Agios Pharmaceuticals, Inc. - CEO & Director

Thanks, Steve. I think we're going to show our forward-looking statements real quick first. Thanks, everybody, for joining us this morning or this afternoon, depending on what time zone you're in. We appreciate your interest in our story.

So here is today's agenda. I'll be very brief with my opening remarks, and then I'll turn it over to our Chief Medical Officer, Dr. Chris Bowden, who will go through mitapivat's mechanism of action for you. And he will also speak about the burden of pyruvate kinase deficiency, and you'll find that one of our abstracts and presentations for EHA is exactly on that topic, and it's part of the overall story of why we think mitapivat's going to be an important

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot